

Checkpoint Inhibition in the Treatment of Cancer: Building the New Standard of Care Across Multiple Solid Tumors and Understanding the Role of Pembrolizumab

Friday, 19 October 2018

18:00 – 20:00

Satellite Symposium
Sponsored by MSD

Messe Munich
Hall A1 – Room 16
Munich, Germany

Chair: Eric Van Cutsem (Belgium)

CHAIR

Eric Van Cutsem

University Hospital Gasthuisberg/Leuven
Leuven, Belgium

FACULTY

Reinhard Dummer

Department of Dermatology
University Hospital of Zurich
Zurich, Switzerland

Heather McArthur

Samuel Oschin Comprehensive
Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California, USA

Evan Y. Yu

Genitourinary Medical Oncology
Research Group
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, USA

Educational Objectives

- Establish a better understanding of the latest clinical data for pembrolizumab and other checkpoint inhibitors that may evolve clinical practice in multiple solid tumors, specifically in melanoma, gastrointestinal (GI), genitourinary (GU), and breast and gynecology (GYN) cancers
- Present a faculty perspective on pembrolizumab and other checkpoint inhibitors and their potential to improve treatment algorithms, response rates, and survival for future patients

AGENDA

18:00 – 18:10	Welcome and Introduction	Eric Van Cutsem
18:10 – 18:30	Checkpoint Inhibitors Across the Melanoma Landscape	Reinhard Dummer
18:30 – 18:50	Treatment of GI Cancers With Checkpoint Inhibitors: Are We on the Edge of a New Era?	Eric Van Cutsem
18:50 – 19:10	Checkpoint Inhibition for the Treatment of Genitourinary Cancers	Evan Yu
19:10 – 19:30	Emergent Women's Cancers Therapies: Catalyst to Transform Standard of Care	Heather McArthur
19:30 – 20:00	Q&A and Closing Remarks	Eric Van Cutsem